Skip to content
Press Room
Axon Therapies is a private company developing a minimally invasive therapy that aims to address a root cause of heart failure. Check-in here for the latest news.

Axon Therapies’ implant-free, catheter-based procedure aims to restore volume balance, stop disease progression and improve patient heart failure symptoms.

Derived from an existing clinical procedure, splanchnic ablation for volume management (SAVM) using the Satera™ Ablation System enables targeted ablation of the overactive sympathetic nervous system, a key driver of worsening heart failure.

Axon, founded by proven medtech incubator Coridea, is funded by leading healthcare investors, including Deerfield ManagementAction Potential Venture Capital, and a confidential strategic investor.

Sign-up For Press Alerts

    The Satera Ablation System is an investigational device and is not currently approved for clinical use in any geography.

    CAUTION – Investigational Device. Limited by Federal (or United States) law to Investigational Use.

    ©2021 Axon Therapies Inc. All rights reserved. Satera is a trademark of Axon Therapies, Inc.